Eli Lilly & Co. vs. Lantern Pharma Inc. Common Stock
Eli Lilly & Co. and Lantern Pharma Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| LLY | LTRN | |
|---|---|---|
| Market Cap | $1.02 trillion | $12.85 million |
| Revenue (TTM) | — | — |
| Net Income (TTM) | — | $-18,652,935 |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | LTRN | |
|---|---|---|
| Price / Book | — | -3.99 |
LLY and LTRN split the valuation factors evenly.
Profitability
| LLY | LTRN | |
|---|---|---|
| Return on Equity | — | 579.78% |
LLY and LTRN split the profitability factors evenly.
Dividend
| LLY | LTRN | |
|---|---|---|
| Dividend Yield | 0.60% | — |
LLY and LTRN split the dividend factors evenly.
Risk & Sentiment
| LLY | LTRN | |
|---|---|---|
| Short Interest | 1.29% | 0.21% |
LTRN leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, LTRN overview, LTRN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.